To test the hypothesis that new-onset atrial fibrillation is related to clinical heart failure progression , in @ patients without atrial fibrillation at randomization in the Beta-blocker Evaluation of Survival Trial we measured clinical endpoints in patients who did ( Group @ , n = @ ) or did not ( Group @ , n = @ ) develop new-onset atrial fibrillation .